Recall conducted overseas Of 2 batches Of Artesunate (Dihydroartemisinin-12-A-Succinate) Powder For Injection 60mg

HSA would like to update healthcare professionals on a recall conducted overseas on 2 batches of artesunate powder for injection (an exempt drug) due to concerns of contamination by E. Coli, E. Fergusonii or Shigella strain, indicating non-sterility of the product and possible contamination at the manufacturing site. The local distributor, Atlantic Pharmaceutical (S) Pte Ltd, has confirmed that these 2 batches have not been supplied locally. As the manufacturing site of this product is still being investigated by the World Health Organisation (WHO), it cannot be ascertained for now if other batches are similarly affected. As a precautionary measure, HSA will be conducting sterility tests on available and incoming batches of Artesunate Powder for Injection 60mg until WHO's investigations has identified the root cause of the problem. Please refer to the letter for more details.